CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Rhea-AI Summary
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 24th Annual Biotech in Europe Forum. John Climaco, the company's CEO, is scheduled to present on Wednesday, September 25, 2024, at 1:55 PM CEST in Basel, Switzerland.
The presentation will be available as a video webcast on demand for registered attendees through the conference presenters portal. Additionally, the company's management team will be available for in-person one-on-one meetings with qualified investors attending the conference.
This event provides CNS Pharmaceuticals with an opportunity to showcase its developments in primary and metastatic cancer treatments, potentially attracting investor interest and fostering industry connections.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CNSP declined 2.10%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST
HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be available on demand for those registered to attend the event and can be accessed through the conference presenters portal.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When and where is CNS Pharmaceuticals (CNSP) presenting at the Biotech in Europe Forum?
Who will be presenting for CNS Pharmaceuticals (CNSP) at the Biotech in Europe Forum?
Will there be a webcast of CNS Pharmaceuticals' (CNSP) presentation at the Biotech in Europe Forum?
What type of meetings will CNS Pharmaceuticals (CNSP) management be available for at the Biotech in Europe Forum?
What is the main focus of CNS Pharmaceuticals (CNSP) as mentioned in the press release?
